Professor and Chairman Department of Gastroenterology and HepatologyKindai University Faculty of Medicine, Japan
Outcomes by key prognostic factors in EMERALD-1: a Phase 3 study of durvalumab ± bevacizumab with transarterial chemoembolization (TACE) in participants with embolization-eligible unresectable hepatocellular carcinoma (uHCC)
Tuesday, April 1, 20254:03 PM – 4:12 PM CT
.jpg)